Saturday, 12 June 2010

FTY720 oral MS treatment gets unanimous FDA approval

Novartis investigational treatment FTY720 (fingolimod) has received unanimous FDA approval for the treatment of patients with relapsing multiple sclerosis (MS).

The advisory committee of FDA, that reviews and decides whether to approve a new treatment, has voted that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5mg dose justified approval.

Multiple Sclerosis Resource Centre Gilenia® (FTY720)